Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

215 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate if rapamune + tacrolimus immunosuppressive prophylaxis is better than the established therapy using cyclosporine and methotrexate, a Nordic prospective multicenter randomized study will be performed. Patients will be randomized to treatment with rapamune combined with tacrolimus, or the established therapy using cyclosporine and methotrexate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients

NCT00519116

Kidney Transplantation

COMPLETED PHASE4

Study Evaluating Sirolimus in Kidney Transplant Recipients

NCT00195273

Graft vs Host Disease Kidney Transplantation

COMPLETED PHASE3

Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT

NCT06348602

Ocular Graft-versus-host Disease

RECRUITING PHASE1/PHASE2

Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.

NCT02936505

Lung Transplantation Allografts

ACTIVE_NOT_RECRUITING NA

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685

Mucositis Graft-versus-host Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary endpoint The primary endpoint is grade II-IV acute GVHD in the two groups. GVHD is diagnosed clinically and graded from 0 to IV. The diagnosis is clinical and biopsies from skin, liver and gut is used according to the routines at each participating center.

Other study parameters

1. Time to neutrophils \>0.5 x 109/L.
2. Time to platelets \>20 x 109/L and 50 x 109/L.
3. Platelet level 30 days after transplant.
4. Transfusion requirements of platelets, erythrocytes, granulocyte transfusions during the first 30 days.
5. Non-engraftment (graft failure/rejection).
6. Grade of acute GVHD.
7. Incidence of chronic graft-versus-host disease graded as limited or extensive and mild, moderate and severe.
8. Transplant-related mortality.
9. Probability of relapse in patients with haematological malignancies.
10. Survival.
11. Relapse-free survival.
12. Infections by bacteria, virus and fungi. Cytomegalovirus reactivation is also followed by PCR.
13. Side-effects. Side-effects regarding hematopoiesis, liver test, renal function, cardiac function, neurology, endocrinology, etc., are taken from the patients' charts. These parameters are followed regularly after transplantation.

Inclusion criteria Chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete remission, acute lymphoblastic leukemia (ALL) in complete remission, myelodysplastic syndrome, chronic lymphocytic leukemia, lymphoma, non-malignant disorders, severe aplastic anemia, hemoglobinopathies and metabolic disorders

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graft-versus-host Disease Survival

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cyclosporine + Methotreaxte

Group Type ACTIVE_COMPARATOR

cyclosporine/methotrexate

Intervention Type DRUG

Standard GVHD prophylaxis

sirolimus + tacrolimus

Group Type ACTIVE_COMPARATOR

Sirolimus/tacrolimus

Intervention Type DRUG

Standard GVHD prophylaxis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sirolimus/tacrolimus

Standard GVHD prophylaxis

Intervention Type DRUG

cyclosporine/methotrexate

Standard GVHD prophylaxis

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete remission, acute lymphoblastic leukemia (ALL) in complete remission, myelodysplastic syndrome, chronic lymphocytic leukemia, lymphoma, non-malignant disorders, severe aplastic anemia, hemoglobinopathies and metabolic disorders

Exclusion Criteria

* Recipients of major HLA-mismatched grafts.
* Patients who are addicted to drugs or alcohol.
* Patients who receive other stem cell source than bone marrow or peripheral stem cells, for instance cord blood transplants.
* Patients with relapse or blast crisis of their malignant disease.
* Prior allogeneic transplant using any hematopoietic stem cell source
* Seropositive for the human immunodeficiency virus (HIV)
* Uncontrolled bacterial, viral, or fungal infection (progression of clinical symptoms) Pregnant (positive serum human chorionic gonadotropin \[β-HCG\] test) or breastfeeding within 4 weeks of study entry
* Kidney function: serum creatinine outside the normal range for age, or measured creatinine clearance less than 40 mL/min/1.72m² within 4 weeks of study entry and proteinuria \>0.3 g/day
* Liver function: most recent direct bilirubin, ALT, or AST greater than two times the upper limit of normal within 4 weeks of study entry
* Lung disease: in adults, FVC or FEV1 less than 60% of predicted value (corrected for hemoglobin); in children, overt hypoxemia, as measured by an oxygen saturation of less than 92% within 4 weeks of study entry
* Cardiac ejection fraction of less than 45% in adults and children, or less than 26% shortening fraction in children within 4 weeks of study entry
* Cholesterol level greater than 300 mg/dL or triglyceride level greater than 300 mg/dL while being treated, or not on appropriate lipid-lowering therapy within 4 weeks of study entry
* Karnofsky score \<70%
* Prior history of allergy to sirolimus
* Requires voriconazole at time of study entry
* Currently receiving another investigational drug unless cleared by the principal investigator and sponsor
* Patients receiving BuCy as conditioning therapy

Minimum Eligible Age

6 Months

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No